Villiger, P M

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 15.

Schirmer, J H; Aries, P M; Balzer, K; Berlit, P; Bley, T A; Buttgereit, F; Czihal, M; Dechant, C; Dejaco, C; Garske, U; Henes, J; Holle, J U; Holl-Ulrich, K; Lamprecht, P; Nölle, B; Moosig, F; Rech, J; Scheuermann, K; Schmalzing, M; Schmidt, W A; ... (2020). [S2k guidelines (executive summary): management of large-vessel vasculitis]. Zeitschrift für Rheumatologie, 79(9), pp. 937-942. Springer-Medizin-Verlag 10.1007/s00393-020-00894-0

Schirmer, J H; Aries, P M; Balzer, K; Berlit, P; Bley, T A; Buttgereit, F; Czihal, M; Dechant, C; Dejaco, C; Garske, U; Henes, J; Holle, J U; Holl-Ulrich, K; Lamprecht, P; Nölle, B; Moosig, F; Rech, J; Scheuermann, K; Schmalzing, M; Schmidt, W A; ... (2020). [S2k guidelines: management of large-vessel vasculitis]. Zeitschrift für Rheumatologie, 79(Suppl 3), pp. 67-95. Springer-Medizin-Verlag 10.1007/s00393-020-00893-1

Aringer, M; Burkhardt, H; Burmester, G R; Fischer-Betz, R; Fleck, M; Graninger, W; Hiepe, F; Jacobi, A M; Kötter, I; Lakomek, H J; Lorenz, H M; Manger, B; Schett, G; Schmidt, R E; Schneider, M; Schulze-Koops, H; Smolen, J S; Specker, C; Stoll, T; Strangfeld, A; ... (2012). Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus, 21(4), pp. 386-401. London: Sage 10.1177/0961203311426569

Winterhalder, L; Eser, P; Widmer, J; Villiger, P M; Aeberli, D (2012). Changes in volumetric BMD of radius and tibia upon antidepressant drug administration in young depressive patients. Journal of musculoskeletal and neuronal interactions, 12(4), pp. 224-9. Nafplion (Greece): International Society of Musculoskeletal and Neuronal Interactions

Ziswiler, H R; Caliezi, G; Villiger, P M (2011). [Musculoskeletal puncture, injection and infiltration: swiss rheumatologists' point of view]. Zeitschrift für Rheumatologie, 70(5), 423-9; quiz 430. Heidelberg: Springer-Verlag 10.1007/s00393-011-0824-4

Bonel, H M; Boller, C; Saar, B; Tanner, S; Srivastav, S; Villiger, P M (2010). Short-term changes in magnetic resonance imaging and disease activity in response to infliximab. Annals of the rheumatic diseases, 69(1), pp. 120-5. London: BMJ Publishing Group 10.1136/ard.2008.103200

Jüni, P; Low, N; Reichenbach, S; Villiger, P M; Williams, S; Dieppe, P A (2010). Gender inequity in the provision of care for hip disease: population-based cross-sectional study. Osteoarthritis and cartilage, 18(5), pp. 640-645. Amsterdam: Elsevier 10.1016/j.joca.2009.12.010

Schmid, L; Müller, M; Treumann, T; Arnold, W; Möller, B; Aeberli, D; Villiger, P M (2009). Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab. Arthritis & rheumatism, 60(6), pp. 1632-4. Hoboken, N.J.: Wiley-Blackwell 10.1002/art.24577

Matulis, G; Jüni, P; Villiger, P M; Gadola, S D (2008). Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Annals of the rheumatic diseases, 67(1), pp. 84-90. London: BMJ Publishing Group 10.1136/ard.2007.070789

Gengenbacher, M; Sebald, H-J; Villiger, P M; Hofstetter, W; Seitz, M (2008). Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Annals of the rheumatic diseases, 67(5), pp. 620-4. London: BMJ Publishing Group 10.1136/ard.2007.076711

Häupl, T; Østensen, M; Grützkau, A; Burmester, G-R; Villiger, P M (2008). Interaction between rheumatoid arthritis and pregnancy: correlation of molecular data with clinical disease activity measures. Rheumatology, 47 Suppl 3, iii19-22. Oxford: Oxford University Press 10.1093/rheumatology/ken157

Förger, F; Marcoli, N; Gadola, S; Möller, B; Villiger, P M; Østensen, M (2008). Pregnancy induces numerical and functional changes of CD4+CD25 high regulatory T cells in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 67(7), pp. 984-90. London: BMJ Publishing Group 10.1136/ard.2007.075283

Turan, B; Pfister, K; Diener, P-A; Hell, M; Möller, B; Boyvat, A; Ergin, S; Villiger, P M (2008). Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scandinavian journal of rheumatology, 37(2), pp. 135-41. Stockholm: Informa Healthcare 10.1080/03009740701747137

Seitz, M; Wirthmüller, U; Möller, B; Villiger, P M (2007). The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology, 46(1), pp. 93-6. Oxford: Oxford University Press 10.1093/rheumatology/kel175

Baki, K; Villiger, P M; Jenni, D; Meyer, T; Beer, J H (2006). Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Annals of the rheumatic diseases, 65(11), pp. 1531-1532. London: BMJ Publishing Group 10.1136/ard.2005.045195

This list was generated on Wed Apr 24 23:23:47 2024 CEST.
Provide Feedback